<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217954</url>
  </required_header>
  <id_info>
    <org_study_id>FIBTC</org_study_id>
    <nct_id>NCT04217954</nct_id>
  </id_info>
  <brief_title>HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC</brief_title>
  <official_title>Hepatic Arterial Infusion Chemotherapy With Oxaliplatin, 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic&#xD;
      agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar&#xD;
      cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy&#xD;
      and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using&#xD;
      intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with&#xD;
      intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary&#xD;
      malignant tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">July 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the start of treatment until disease progression, lost to follow-up or death, up to approximately 3 years</time_frame>
    <description>date from the first treatment until disease progression, lost to follow-up or death, whichever happen first, assessed at least 2 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>From the start of treatment until the end of treatment, up to approximately 3 years</time_frame>
    <description>CR plus PR according to imRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the start of treatment until death or lost to follow-up, up to approximately 3 years</time_frame>
    <description>date from the start of treatment until death or lost to follow-up, whichever happen first, assessed at least 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the start of treatment until the end of treatment, up to approximately 3 years</time_frame>
    <description>type and incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19-9 level</measure>
    <time_frame>From the start of treatment until the end of treatment, up to approximately 3 years</time_frame>
    <description>The change of CA 19-9 before and after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The signal in dynamic contrast enhanced (DCE)-MRI</measure>
    <time_frame>From the start of treatment until the end of treatment, up to approximately 3 years</time_frame>
    <description>The change of signal in DCE-MRI before and after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in diffusion weighted imaging (DWI) of MRI</measure>
    <time_frame>From the start of treatment until the end of treatment, up to approximately 3 years</time_frame>
    <description>The change in DWI of MRI, including apparent diffusion coefficient (ADC), before and after the treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Advanced Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>OXA, 5-FU and Bev plus Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OXA, 5-FU and bevacizumab plus Toripalimab</intervention_name>
    <description>concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.&#xD;
B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.&#xD;
The concomitant treatment repeat every three week, up to 6 cycles.&#xD;
Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks.</description>
    <arm_group_label>OXA, 5-FU and Bev plus Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biliary tract cancer proved by histology or cytology&#xD;
&#xD;
          2. Metastatic advanced or locally advanced unresectable biliary tract cancer, including&#xD;
             gallbladder cancer, intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma,&#xD;
             decided by hepatobiliary doctor and radiologist.&#xD;
&#xD;
          3. At least one measurable lesion within liver;&#xD;
&#xD;
          4. No prior intra-arterial/systemic chemotherapy or other systemic therapies&#xD;
&#xD;
          5. Prior resection, TACE or ablation will be allowed.&#xD;
&#xD;
          6. Age from 18 years old to 80 years old.&#xD;
&#xD;
          7. the performance of Eastern Cooperative Oncology Group (ECOG) &lt;2&#xD;
&#xD;
          8. Child-Pugh A or Child-Pugh B (≤ grade 7).&#xD;
&#xD;
          9. Expectant survival time ≥ 3 months.&#xD;
&#xD;
         10. Baseline blood count test and blood biochemical must meet following criteria:&#xD;
&#xD;
               1. Hemoglobin ≥ 90 g/L;&#xD;
&#xD;
               2. Absolute neutrophil count ≥ 1.5×10^9/L;&#xD;
&#xD;
               3. Blood platelet count ≥ 100×10^9/L;&#xD;
&#xD;
               4. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times of&#xD;
                  upper limit of normal (ULN);&#xD;
&#xD;
               5. Total bilirubin ≤ 2 times of ULN;&#xD;
&#xD;
               6. Serum creatinine ≤ 1.5 times of ULN;&#xD;
&#xD;
               7. Albumin ≥ 30 g/L.&#xD;
&#xD;
         11. Patients sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distal cholangiocarcinoma.&#xD;
&#xD;
          2. Allergic to contrast agent.&#xD;
&#xD;
          3. Pregnant or lactational.&#xD;
&#xD;
          4. Allergic to 5-fluorouracil, or have metabolic disorder of 5-fluorouracil.&#xD;
&#xD;
          5. More than 80 years old.&#xD;
&#xD;
          6. Previous systematic chemotherapy or radiotherapy.&#xD;
&#xD;
          7. Child-Pugh C or Child-Pugh B (≥ grade 8).&#xD;
&#xD;
          8. Coinstantaneous a lot of malignant hydrothorax or ascites.&#xD;
&#xD;
          9. History of organ transplantation (including bone marrow auto-transplantation and&#xD;
             peripheral stem cell transplantation).&#xD;
&#xD;
         10. Coinstantaneous infection and need anti-infection therapy.&#xD;
&#xD;
         11. Hepatitis B virus DNA load ≥ 100 IU/ml (patients whose hepatitis B virus DNA load&#xD;
             decreased to &lt; 100 IU/ml after anti-virus therapy could be enrolled).&#xD;
&#xD;
         12. Coinstantaneous peripheral nervous system disorder or with history of obvious mental&#xD;
             disorder and central nervous system disorder.&#xD;
&#xD;
         13. Diagnosed other kinds of malignant within 5 years, except for non-melanoma skin cancer&#xD;
             and carcinoma in situ of cervix.&#xD;
&#xD;
         14. Without legal capacity.&#xD;
&#xD;
         15. Impact the study because of medical or ethical reasons.&#xD;
&#xD;
         16. Uncorrectable coagulation disorder.&#xD;
&#xD;
         17. Obvious abnormal in ECG or obvious clinical symptoms of heart disease, like congestive&#xD;
             heart failure (CHF), coronary heart disease with obvious clinical symptoms,&#xD;
             unmanageable arrhythmia and hypertension.&#xD;
&#xD;
         18. History of myocardial infarction within 12 months, or Grade III/IV of heart function.&#xD;
&#xD;
         19. Severe liver disease (like cirrhosis), renal disease, respiratory disease,&#xD;
             unmanageable diabetes or other kinds of systematic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaodong Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Interventional Therapy, Peking University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaodong Wang, MD</last_name>
    <phone>0086-18611586227</phone>
    <email>tigat@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Wang, MD</last_name>
      <phone>0086-18611586227</phone>
      <email>tigat@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Park J, Kim MH, Kim KP, Park DH, Moon SH, Song TJ, Eum J, Lee SS, Seo DW, Lee SK. Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study. Gut Liver. 2009 Dec;3(4):298-305. doi: 10.5009/gnl.2009.3.4.298. Epub 2009 Dec 31.</citation>
    <PMID>20431764</PMID>
  </reference>
  <reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </reference>
  <reference>
    <citation>Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK, Gamblin TC. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015 Feb;111(2):213-20. doi: 10.1002/jso.23781. Epub 2014 Sep 1. Review.</citation>
    <PMID>25176325</PMID>
  </reference>
  <reference>
    <citation>Wang X, Hu J, Cao G, Zhu X, Cui Y, Ji X, Li X, Yang R, Chen H, Xu H, Liu P, Li J, Li J, Hao C, Xing B, Shen L. Phase II Study of Hepatic Arterial Infusion Chemotherapy with Oxaliplatin and 5-Fluorouracil for Advanced Perihilar Cholangiocarcinoma. Radiology. 2017 May;283(2):580-589. doi: 10.1148/radiol.2016160572. Epub 2016 Nov 7.</citation>
    <PMID>27820684</PMID>
  </reference>
  <reference>
    <citation>Gao F, Yang C. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. Curr Cancer Drug Targets. 2020;20(1):3-18. doi: 10.2174/1568009619666191114110359. Review.</citation>
    <PMID>31729943</PMID>
  </reference>
  <reference>
    <citation>Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124. doi: 10.1016/j.semcancer.2017.12.002. Epub 2017 Dec 8. Review.</citation>
    <PMID>29229461</PMID>
  </reference>
  <reference>
    <citation>Mathew M, Enzler T, Shu CA, Rizvi NA. Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther. 2018 Jun;186:130-137. doi: 10.1016/j.pharmthera.2018.01.003. Epub 2018 Jan 31. Review.</citation>
    <PMID>29352857</PMID>
  </reference>
  <reference>
    <citation>Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy. 2015;7(3):309-16. doi: 10.2217/imt.14.111. Review.</citation>
    <PMID>25804482</PMID>
  </reference>
  <reference>
    <citation>Longo V, Brunetti O, Azzariti A, Galetta D, Nardulli P, Leonetti F, Silvestris N. Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers (Basel). 2019 Apr 15;11(4). pii: E539. doi: 10.3390/cancers11040539. Review.</citation>
    <PMID>30991686</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Xiaodong Wang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatic arterial infusion chemotherapy</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>5-fluorouracil</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>Toripalimab</keyword>
  <keyword>advanced biliary tract cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>signed informed consent with patients</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

